Gip / glp1 co-agonist compounds

MD3827015T2Active Publication Date: 2026-08-31ELI LILLY & CO

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: MDE20210499T
Authority / Receiving Office: MD · MD
Patent Type: Patents
Current Assignee / Owner
Priority Date: 2019-07-22
Filing Date: 2019-07-22
Publication Date: 2026-08-31
Estimated Expiration: 2039-07-22

Application Information

Patent Timeline

22 Jul 2019

Priority

22 Jul 2019

Application

MDE20210499T

31 Aug 2026

Publication

MD3827015T2

IPC: C07K14/605; A61K38/00; A61K38/26; A61P3/04; A61P3/10; C07K14/575

CPC: C07K14/605; C07K14/575; A61P3/10; A61P3/04; A61P1/16; A61P3/06; A61P3/00; A61K38/00

Inventors: PATEL Phenil Jayantilal; QU Hongchang

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to compounds that exhibit activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds that exhibit an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that can be administered orally. The compounds according to the claims may be useful in the treatment of type 2 diabetes mellitus ("T2DM"). The compounds may also be used in the treatment of obesity.

Need to check novelty before this filing date? Find Prior Art